Hallucinations and sleep disturbances in Parkinson's disease

Neurology

Volumn 63, Issue 8 SUPPL. 3, 2004, Pages

  Kulisevsky, Jaime ^a,b   Roldan, Eliana ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MODAFINIL; NEUROLEPTIC AGENT; OLANZAPINE; PSYCHOSTIMULANT AGENT; QUETIAPINE; RISPERIDONE;

AGRANULOCYTOSIS; COGNITION; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISABILITY; DISEASE EXACERBATION; DOPAMINERGIC SYSTEM; DRUG MEGADOSE; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; NEUROLOGIC DISEASE; PARKINSON DISEASE; PARKINSONISM; POLYSOMNOGRAPHY; PRIORITY JOURNAL; PSYCHOSIS; RATING SCALE; REM SLEEP; REVIEW; SEDATION; SIDE EFFECT; SLEEP DISORDER; VISUAL HALLUCINATION;

EID: 7044253084     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.63.8_suppl_3.s28     Document Type: Review

References (38)

1. Barnes J, David, A. Visual hallucinations in Parkinson's disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry 2001;70:727-733.
2. Porteous HB, Ross DN. Mental symptoms in parkinsonism following benzhexol hydrochloride therapy. BMJ 1956;4985:138-140.
3. Celesia GG, Barr AN. Psychosis and other psychiatric manifestations of levodopa therapy. Arch Neurol 1970;23:193-200.
4. Horowski R. Psychiatric side-effects of high-dose lisuride therapy in parkinsonism. Lancet 1986;2:510.
5. Feinberg WM, Rapcsak SZ. "Peduncular hallucinosis" following paramedical thalamic infarction. Neurology 1989;39:1535-1536.
6. Teunisse RJ, Cruysberg JR, Hoefnagels WH, et al. Visual hallucinations in psychologically normal people: Charles Bonnet's syndrome. Lancet 1996;347:794-797.
7. Manford M, Andermann F. Complex visual hallucinations. Clinical and neurobiological insights. Brain 1998;121:1819-1840.
8. Cummings JL. Behavioral complications of drug treatment of Parkinson's disease. J Am Geriatr Soc 1991;39:708-716.
9. Moskovitz C, Moses H, Klawans HL. Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 1978;135:669-675.
10. Goetz C, Stebbins G. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 1995;45:669-671.
11. Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson's disease. Arch Neurol 1996;53:1265-1268.
12. Holroyd S. Visual hallucinations in a geriatric psychiatry clinic: prevalence and associated diagnoses. J Geratr Psychiatry Neurol 1996;9:171-175.
13. Graham JM, Grunewald RA, Sagar HJ. Hallucinosis in idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;63:434-440.
14. Aarsland D, Larsen J, Cummins J, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 1999;56:595-601.
15. Fenelon G, Mahieux F, Huon R, et al. Hallucinations in Parkinson's disease. Prevalence, phenomenology and risk factors. Brain 2000;123:733-745.
16. Teunisse RJ, Cruysberg JR, Hoefnagels WH, et al. Visual hallucinations in psychologically normal people: Charles Bonnet's syndrome. Lancet 1996;347:794-797.
17. Holroyd S, Currie L, Wooten G. Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psichiatry 2001;70:734-738.
18. Poewe W. Psychosis in Parkinson's disease. Mov Disord 2003;18(suppl 6):S80-87.
19. Barnes J, Boubert L, Harris J, et al. Reality monitoring and visual hallucinations in Parkinson's disease. Neuropsychology 2003;41:565-574.
20. Pappert EJ, Goetz CG, Niederman FG, et al. Sleep fragmentation, and altered dream phenomena in PD. Mov Disord 1999;14:117-121.
21. Commella CL, Tanner CM, Ristanovic RK. Polysomnographic sleep measures in Parkinson's disease patients with treatment induced hallucinations. Ann Neurol 1993;34:710. Abstract.
22. Arnulf I, Konofal E, Merino-Andreu M, et al. Parkinson's disease and sleepiness. An integral part of PD. Neurology 2002;58:1019-1024.
23. Manni R, Pacchetti C, Terzaghi M, et al. Hallucinations and sleep-wake cycle in PD: A 24-hour continuous polysomnographic study. Neurology 2002;59:1979-1981.
24. Jellinger K. New developments in the pathology of Parkinson's disease. Adv Neurol 1990;53:1-16.
25. Askenasy JJ. Sleep disturbances in Parkinsonism. J Neural Transm 2003;110:125-150.
26. Boeve (Bradley) BF, Silber MH, Ferman TJ, et al. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord 2001;16:622-630.
27. The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999;340:757-763.
28. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 2000;15:201-211.
29. Dewey RB, O'Suillebeabhain PE. Treatment of drug-induced psychosis with quetiapine and clozapine. Neurology 2000;55:1753-1754.
30. Ondo WG, Levy JK, Vuong KD, et al. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 2002;17:1031-1035.
31. Breier A, Sutton VK, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with PD. Biol Psychiatry 2002;52:438-445.
32. Mohr E, Mendis T, Hildebrand K, De Deyn PP. Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial. Mov Disord 2000;15:1230-1237.
33. Connemann BJ, Schönfeld-Lecuona C. Ziprasidone in Parkinson's disease psychosis. Can J Psychiatry 2004;49:73. Abstract.
34. Nakano I, Hirano A. Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease. Ann Neurol 1984;15:415-418.
35. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial. Mov Disord 2001;16:1171-1174.
36. Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil treatment in Parkinson's disease with dementia: a double-blind, placebo-controlled crossover study. J Neurol Neurosurg Psychiatry 2002;73:354. Abstract.
37. Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with PD. Clin Neuropharmacol 2002;25:107-110.
38. Adler CH, Caviness JN, Hentz JG, et al. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord 2003;18:287-293.